Intellia Therapeutics, Inc.
NTLA
$8.84
$0.202.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.87M | 9.11M | 6.96M | 28.94M | -1.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.87M | 9.11M | 6.96M | 28.94M | -1.92M |
| Cost of Revenue | 116.88M | 123.38M | 114.21M | 111.85M | 108.98M |
| Gross Profit | -104.00M | -114.27M | -107.25M | -82.91M | -110.90M |
| SG&A Expenses | 32.44M | 30.50M | 31.79M | 31.09M | 28.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 149.32M | 153.88M | 146.00M | 142.94M | 137.98M |
| Operating Income | -136.45M | -144.77M | -139.04M | -114.00M | -139.89M |
| Income Before Tax | -128.90M | -135.71M | -146.98M | -107.44M | -132.16M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -128.90M | -135.71M | -146.98M | -107.44M | -132.16M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.90M | -135.71M | -146.98M | -107.44M | -132.16M |
| EBIT | -136.45M | -144.77M | -139.04M | -114.00M | -139.89M |
| EBITDA | -133.88M | -142.16M | -136.44M | -111.49M | -137.43M |
| EPS Basic | -1.27 | -1.34 | -1.52 | -1.13 | -1.46 |
| Normalized Basic EPS | -0.77 | -0.82 | -0.82 | -0.66 | -0.91 |
| EPS Diluted | -1.27 | -1.34 | -1.52 | -1.13 | -1.46 |
| Normalized Diluted EPS | -0.77 | -0.82 | -0.82 | -0.66 | -0.91 |
| Average Basic Shares Outstanding | 101.86M | 101.00M | 96.98M | 95.50M | 90.46M |
| Average Diluted Shares Outstanding | 101.86M | 101.00M | 96.98M | 95.50M | 90.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |